BIRC6 and non-small cell lung carcinoma: Prior studies in patients with non-small-cell lung cancer (NSCLC) revealed that the increased expression of BIRC6, an inhibitor of apoptosis family members, was correlated with poor 3-year relapse-free survival and with metastasis and predicted resistance to chemotherapy.36